27 Target ID & Validation CROs

What is Target ID and validation, and when do you need it?

Target identification and validation is the first real fork in a drug program. Target ID is finding the gene, protein, or pathway that plausibly drives a disease. Validation is the harder, more expensive half: building enough evidence that hitting that target will change the disease, and that it is druggable, before you commit a budget to assays, screening, and chemistry. Get this wrong and everything downstream inherits the mistake, which is why so much of clinical attrition traces back to targets that were never properly de-risked.

You need this work at the very start of discovery, when you have a disease biology hypothesis but no validated point of intervention yet. Sometimes it is a fresh target nobody has drugged. Sometimes it is a target a competitor is chasing and you want independent confirmation before you follow. Either way the question is the same: does perturbing this target move the biology you care about, in a model that means something, and is there a realistic way to drug it. A CRO running CRISPR knockout and knockdown, RNAi, and target-engagement readouts answers the first part; genetic association and human evidence answers whether the link holds in people, not just a cell line.

The practical reason to validate hard here is cost asymmetry. A target-validation package is a few months of focused work against a screening campaign and years of chemistry that follow. Spending properly on validation, and being willing to kill a target that does not hold up, is the cheapest risk reduction available in the whole development chain. Most of this is research-grade, non-GLP science, so you are buying scientific judgment and clean data rather than a regulatory deliverable.

What does a Target ID and validation CRO actually do?

The menu varies by target class and by how much is already known, but a strong Target ID and validation CRO typically covers the work below. Most programs use several of these in sequence, starting with the cheapest genetic evidence and moving toward functional confirmation only when the early signal holds.

Two distinctions are worth pinning down with any vendor before you scope. First, genetic validation (does human data link this target to the disease) versus functional validation (does perturbing it in a model change the phenotype) answer different questions, and you usually want both. Second, druggability assessment, whether the target has a tractable binding pocket, a surface antibody can reach, or a degradable handle, decides whether a validated target is even worth a screening campaign. A target can be biologically real and still not be drugged in your chosen modality.

• Target identification: literature and pathway mining, omics and differential-expression analysis (RNA-seq, proteomics), and disease-network analysis to nominate candidate targets.
• Genetic association and human evidence: GWAS, Mendelian and rare-disease genetics, eQTL and Open Targets-style scoring to check the target-to-disease link holds in people, not just a model.
• CRISPR functional validation: knockout, CRISPRi knockdown, and CRISPRa overexpression, including arrayed and pooled screens, to test whether perturbing the target changes the disease-relevant phenotype.
• RNAi and antisense knockdown: siRNA and shRNA studies as an orthogonal method to confirm a CRISPR result rather than relying on one technology.
• Target-engagement and mechanism: CETSA, reporter assays, and pathway readouts that show the target is actually being hit and that the downstream biology responds.
• Druggability and tractability assessment: structural and pocket analysis, modality fit (small molecule, antibody, oligonucleotide, degrader), and an early ligandability read.
• Model context: in vitro cell lines, patient-derived and primary cells, organoids, and where justified an early in vivo knockout to test whether the target effect carries into a whole organism.

How do you choose a Target ID and validation CRO?

The first filter is fit to your target class and biology, not the size of the logo. A group that runs flawless pooled CRISPR screens in cancer cell lines may be the wrong choice for a CNS target that only behaves in primary neurons or an organoid, and a genetics-heavy informatics shop will not give you the wet-lab functional confirmation you need. Ask for relevant work in your therapeutic area and target class, and confirm the scientists you would actually work with have validated this kind of target before.

Validation depends on orthogonality and honesty more than on volume. A target confirmed by one CRISPR screen is a lead; a target confirmed by CRISPR, an orthogonal RNAi knockdown, a clean rescue, and supportive human genetics is a real program. So weigh a CRO partly on whether they push back, run the confirmatory experiment you did not ask for, and report the targets that failed instead of dressing up a weak signal. In early discovery the cost of a false positive is paid downstream in a screening campaign and chemistry you never should have funded.

Use the checklist below when you compare two or three vendors against the same written scope.

• Quality and GxP status: target validation is research-grade and non-GLP, so look for documented SOPs, electronic-notebook practice, reproducibility data (for example screen QC and hit-confirmation rates), and traceable raw data rather than a GLP certificate.
• Capacity and lead time: confirm current queue and realistic turnaround on a screen and its confirmation, since a great lab booked solid can be slower than a good lab with an open slot.
• Modality and indication fit: match the CRO to your target class and intended modality (small molecule, antibody, oligonucleotide, degrader), and check they run the right cell systems for your disease, not just an easy immortalized line.
• Region and regulatory track record: this work rarely files with a regulator, but if any in vivo step or future handoff feeds a regulatory package, confirm the vendor's data standards and where they operate.
• Data quality and orthogonal confirmation: ask how they confirm a hit (a second method, a rescue, on-target controls for CRISPR), what their assay acceptance criteria are, and whether published or peer-reviewed work backs their methods.
• IP and confidentiality: settle ownership of validation data and any platform-derived findings in writing, and make sure a CDA is in place before you disclose an undisclosed target you may not want named.